ELEPHAS PRESENTS NEW DATA SHOWING elive™ PLATFORM MEASURES CYTOTOXICITY ENDPOINTS IN TARGETED THERAPIES, EXTENDING PLATFORM'S POWER

Barchart · 2d ago

New AACR D3 data mark a significant milestone for functional precision medicine, arriving as ASCO formally affirms the field as the future of care

MADISON, Wis., July 24, 2026 /PRNewswire/ -- Elephas Biosciences Corporation, a private company that has developed an innovative live tissue platform for immunotherapy response prediction, announced new data at the American Association for Cancer Research Drug Discovery and Development (AACR D3) conference. The data show that the elive platform, already shown to measure response to immune checkpoint inhibitors (ICIs), now can support targeted therapies as well.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.